Free Trial

Elanco Animal Health (ELAN) Competitors

Elanco Animal Health logo
$14.64 -0.08 (-0.54%)
Closing price 07/3/2025 03:30 PM Eastern
Extended Trading
$14.65 +0.01 (+0.07%)
As of 07/3/2025 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ELAN vs. ONC, BNTX, TEVA, INSM, SMMT, ITCI, GMAB, RDY, QGEN, and MRNA

Should you be buying Elanco Animal Health stock or one of its competitors? The main competitors of Elanco Animal Health include BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Insmed (INSM), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.

Elanco Animal Health vs. Its Competitors

BeOne Medicines (NASDAQ:ONC) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 6.6% of BeOne Medicines shares are owned by company insiders. Comparatively, 0.9% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BeOne Medicines currently has a consensus target price of $320.67, suggesting a potential upside of 30.62%. Elanco Animal Health has a consensus target price of $15.33, suggesting a potential upside of 4.74%. Given BeOne Medicines' stronger consensus rating and higher probable upside, equities analysts clearly believe BeOne Medicines is more favorable than Elanco Animal Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BeOne Medicines
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Elanco Animal Health
0 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Elanco Animal Health has a net margin of 8.43% compared to BeOne Medicines' net margin of -9.40%. Elanco Animal Health's return on equity of 7.54% beat BeOne Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
BeOne Medicines-9.40% -7.55% -4.42%
Elanco Animal Health 8.43%7.54%3.57%

In the previous week, Elanco Animal Health had 8 more articles in the media than BeOne Medicines. MarketBeat recorded 11 mentions for Elanco Animal Health and 3 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.61 beat Elanco Animal Health's score of 0.37 indicating that BeOne Medicines is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BeOne Medicines
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Elanco Animal Health
2 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

BeOne Medicines has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500.

Elanco Animal Health has higher revenue and earnings than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeOne Medicines$3.81B7.06-$644.79M-$3.72-65.99
Elanco Animal Health$4.44B1.64$338M$0.7419.78

Summary

Elanco Animal Health beats BeOne Medicines on 10 of the 16 factors compared between the two stocks.

Get Elanco Animal Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELAN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ELAN vs. The Competition

MetricElanco Animal HealthMED IndustryMedical SectorNYSE Exchange
Market Cap$7.27B$3.91B$5.53B$20.72B
Dividend YieldN/A1.27%5.24%3.72%
P/E Ratio19.7835.6227.5228.09
Price / Sales1.6418.00421.0238.30
Price / Cash6.5024.0336.8922.53
Price / Book1.194.398.044.58
Net Income$338M$189.47M$3.18B$986.06M
7 Day Performance2.27%-1.09%2.90%2.79%
1 Month Performance8.97%-4.38%3.70%5.46%
1 Year Performance2.92%8.86%36.15%15.06%

Elanco Animal Health Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELAN
Elanco Animal Health
2.2364 of 5 stars
$14.64
-0.5%
$15.33
+4.7%
+3.6%$7.27B$4.44B19.789,000News Coverage
Analyst Forecast
ONC
BeOne Medicines
3.424 of 5 stars
$242.07
+0.4%
$320.67
+32.5%
N/A$26.53B$3.81B-65.079,000
BNTX
BioNTech
2.362 of 5 stars
$106.47
-0.2%
$137.86
+29.5%
+37.3%$25.59B$2.98B-31.313,080
TEVA
Teva Pharmaceutical Industries
4.1423 of 5 stars
$16.76
flat
$24.13
+43.9%
+1.4%$19.22B$16.54B-14.5736,800
INSM
Insmed
4.1525 of 5 stars
$100.64
+1.2%
$106.80
+6.1%
+58.9%$19.09B$363.71M-16.91740Positive News
SMMT
Summit Therapeutics
2.528 of 5 stars
$21.28
+3.3%
$35.09
+64.9%
+253.3%$15.80B$700K-62.59110Trending News
Analyst Forecast
Options Volume
ITCI
Intra-Cellular Therapies
0.982 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560
GMAB
Genmab A/S
3.5842 of 5 stars
$20.66
+0.8%
$37.60
+82.0%
-18.8%$13.25B$3.12B11.742,682
RDY
Dr. Reddy's Laboratories
2.8117 of 5 stars
$15.03
-0.3%
$16.95
+12.8%
-0.9%$12.55B$3.81B22.7727,811
QGEN
Qiagen
4.0422 of 5 stars
$48.07
+0.6%
$49.40
+2.8%
+22.5%$10.69B$1.98B120.525,765Dividend Announcement
MRNA
Moderna
4.3809 of 5 stars
$27.59
+1.6%
$46.61
+68.9%
-73.7%$10.67B$3.24B-3.165,800Options Volume

Related Companies and Tools


This page (NYSE:ELAN) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners